⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL87986 | 0.69 | — | — | |
| SCHEMBL1258305 | 0.69 | — | — | |
| SCHEMBL7715360 | 0.67 | — | — | |
| SCHEMBL6971277 | 0.67 | — | — | |
| SCHEMBL7158013 | 0.67 | — | — | |
| SCHEMBL1120949 | 0.67 | — | — | |
| SCHEMBL14541 | 0.67 | — | — | |
| SCHEMBL9471886 | 0.65 | — | — | |
| SCHEMBL3370615 | 0.65 | — | — | |
| SCHEMBL28838548 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303283-A2 | ANTI-CANCER COMBINATION THERAPY | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2011-04-06 | — | — | EP | claimed |
| US-20110065663-A1 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D | 2011-03-17 | — | — | US | claimed |
| US-7879852-B2 | such as (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide, used for the treatment of obesity, diabetes, inflammation and erectile dysfunction | LG LIFE SCIENCES LTD. (KR) | 2011-02-01 | — | — | US | claimed |
| US-20090298829-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2009-12-03 | — | — | US | claimed |
| WO-2009138507-A2 | ANTI-CANCER COMBINATION THERAPY | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2009-11-19 | — | — | WO | claimed |
| WO-2008007930-A9 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD (KR) | 2009-04-02 | — | — | WO | claimed |
| EP-2041120-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd. (KR) | 2009-04-01 | — | — | EP | claimed |
| WO-2008007930-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| EP-0884051-B1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2004-12-15 | — | — | EP | claimed |
| EP-0763529-B1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | EP | claimed |
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | claimed |
| US-6255314-B1 | Cancerous metastasis inhibitors containing uracil derivatives | TAIHO CHARMACEUTICAL CO., LTD. (JP) | 2001-07-03 | — | — | US | claimed |
| US-6159969-A | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-12-12 | — | — | US | claimed |
| US-6110967-A | USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2000-08-29 | — | — | US | claimed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | claimed |
| EP-0884051-A1 | CANCEROUS METASTASIS INHIBITORS CONTAINING URACIL DERIVATIVES | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-12-16 | — | — | EP | claimed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | claimed |
| WO-2024108198-A2 | METHODS OF TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-5744475-A | 4-N-HET-METHYLURACIL DERIVATIVES; THYMIDINE PHOSPHORYLASE INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| EP-0763529-A1 | URACIL DERIVATIVES, AND ANTITUMOR EFFECT POTENTIATOR AND ANTITUMOR AGENT CONTAINING THE SAME | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1997-03-19 | — | — | EP | disclosed |